InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
60,847.47
(
2.74%
)
Post# of 252592
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 52937

Thursday, 09/27/2007 3:52:42 PM

Thursday, September 27, 2007 3:52:42 PM

Post# of 252592
>Other C1-INHs are in development for HAE, but we believe LEVP will likely receive 7 years of Orphan exclusivity in the U.S. for Cinryze.<

Pharming obviously disagrees. One possibility is that the FDA grants separate orphan exclusivity for prophylactic HAE and acute HAE, although this seems unjustified by the orphan regs themselves.

Comments?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up